AVROBIO (AVRO) investor relations material

Company overview and business model

• Clinical-stage biotechnology company developing therapeutic proteins and antibodies targeting GPCRs, a historically challenging class for biologics.

• Proprietary GEODe™ platform enables discovery of GPCR-targeted biologic medicines for diseases with significant unmet need.

• Lead asset TX45 is in Phase 1b and Phase 2 trials for pulmonary hypertension in heart failure; early data show favorable safety and efficacy signals.

• Second candidate, TX2100, targets Hereditary Hemorrhagic Telangiectasia, with IND-enabling studies underway and Phase 1 planned for late 2025 or early 2026.

• Company recently completed a merger and operates as a smaller reporting company, allowing reduced disclosure obligations.

Financial performance and metrics

• Net tangible book value as of March 31, 2025: $301.0 million, or $16.12 per share.

• After a $100 million offering at $21.34/share, as adjusted net tangible book value would be $17.03 per share, with $397.7 million in net tangible book value.

• Immediate dilution to new investors in the offering is estimated at $4.31 per share.

Use of proceeds and capital allocation

• Net proceeds intended for continued clinical development of pipeline products, working capital, and general corporate purposes.

• May also use proceeds for in-licensing, acquisitions, or investments in complementary businesses, though no current commitments exist.

• Pending use, proceeds will be invested in investment-grade, interest-bearing instruments.